ATE182790T1 - Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege - Google Patents

Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege

Info

Publication number
ATE182790T1
ATE182790T1 AT94914023T AT94914023T ATE182790T1 AT E182790 T1 ATE182790 T1 AT E182790T1 AT 94914023 T AT94914023 T AT 94914023T AT 94914023 T AT94914023 T AT 94914023T AT E182790 T1 ATE182790 T1 AT E182790T1
Authority
AT
Austria
Prior art keywords
actin
contents
respiratory tract
viscosity
pathalogical
Prior art date
Application number
AT94914023T
Other languages
English (en)
Inventor
Thomas P Stossel
Stuart E Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE182790T1 publication Critical patent/ATE182790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94914023T 1993-04-02 1994-04-04 Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege ATE182790T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I

Publications (1)

Publication Number Publication Date
ATE182790T1 true ATE182790T1 (de) 1999-08-15

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914023T ATE182790T1 (de) 1993-04-02 1994-04-04 Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege

Country Status (17)

Country Link
US (2) US5464817A (de)
EP (1) EP0692970B1 (de)
JP (2) JPH08510998A (de)
KR (1) KR100308679B1 (de)
CN (1) CN1107521C (de)
AT (1) ATE182790T1 (de)
AU (1) AU695033B2 (de)
BR (1) BR9405856A (de)
CA (1) CA2159205A1 (de)
DE (1) DE69419907T2 (de)
DK (1) DK0692970T3 (de)
ES (1) ES2135576T3 (de)
GB (1) GB2293102B (de)
GR (1) GR3031753T3 (de)
NO (1) NO953862D0 (de)
SG (1) SG49574A1 (de)
WO (1) WO1994022465A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
CA2210871C (en) * 1995-02-24 2009-04-07 Genentech, Inc. Human dnase i variants
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
CZ297463B6 (cs) * 1995-02-24 2006-12-13 Genentech, Inc. Varianta lidské DNázy I, mající DNA hydrolytickouaktivitu a aminokyselinovou sekvenci mající nejméne 90 % identity s aminokyselinovou sekvencí prírodní lidské DNázy I
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
PT941108E (pt) * 1996-12-04 2003-01-31 Renovo Ltd Cicatrizacao de feridas e tratamento da fibrose
EP1249244A1 (de) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutische Zusammensetzungen zur Behandlung einer g-actin / f-actin-gleichgewicht vermittelten Erkrankung, z.b. einer respiratorischen Erkrankung
AU2002359951B8 (en) * 2001-12-28 2008-11-06 Asubio Pharma Co., Ltd. Promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
EP2335722B1 (de) * 2004-05-12 2019-03-13 The Brigham and Women's Hospital, Inc. Verwendung von Gelsolin zur Behandlung von Infektionen
EP1791566A4 (de) * 2004-08-06 2008-07-16 Nat Jewish Med & Res Center Produkt und verfahren zur hemmung der biofilm-entwicklung
EP1880733A4 (de) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Verfahren zur verlängerung der lebensdauer eines menschen und von tieren
DK3279663T3 (da) 2006-03-15 2021-10-18 Brigham & Womens Hospital Inc Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
US8440622B2 (en) * 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
ES2369547T3 (es) * 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
EP2114460B1 (de) 2007-02-15 2014-07-16 National Jewish Health Zusammensetzungen zur brechung von biofilmen
US9575072B2 (en) * 2008-01-25 2017-02-21 The Brigham And Women's Hospital, Inc. Diagnostic and therapeutic uses of gelsolin in renal failure
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン，ドミトリー 神経変性における治療標的としての細胞外ｄｎａ
WO2019143272A1 (en) 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE69130289T2 (de) * 1990-04-11 1999-06-02 Brigham And Women's Hospital, Boston, Mass. Therapeutische verwendung von actin-bindenden verbindungen
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
AU6625094A (en) 1994-10-24
GB9520020D0 (en) 1995-12-06
DE69419907D1 (de) 1999-09-09
GB2293102A (en) 1996-03-20
CA2159205A1 (en) 1994-10-13
DK0692970T3 (da) 1999-12-06
CN1122108A (zh) 1996-05-08
NO953862L (no) 1995-09-29
EP0692970B1 (de) 1999-08-04
BR9405856A (pt) 1996-03-05
US5464817A (en) 1995-11-07
NO953862D0 (no) 1995-09-29
JP2001302537A (ja) 2001-10-31
KR100308679B1 (ko) 2001-11-30
EP0692970A1 (de) 1996-01-24
US5656589A (en) 1997-08-12
DE69419907T2 (de) 1999-12-09
ES2135576T3 (es) 1999-11-01
SG49574A1 (en) 1998-06-15
GR3031753T3 (en) 2000-02-29
AU695033B2 (en) 1998-08-06
GB2293102B (en) 1996-10-09
JPH08510998A (ja) 1996-11-19
CN1107521C (zh) 2003-05-07
WO1994022465A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
ATE182790T1 (de) Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege
DE69738522D1 (de) Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
EA200100502A1 (ru) СПОСОБЫ И КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ КОНФОРМАЦИОННОЙ СТАБИЛЬНОСТИ БЕЛКА СЕМЕЙСТВА p53
DK0754048T3 (da) Behandling af partielt væksthormon-insentivitetssyndrom
DE69331045D1 (de) Verwendung von igf-1
KR920700667A (ko) 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용
DE68907679D1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweg-geschwuerkrankheiten.
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE69433682D1 (de) Wässrige proteinzusammensetzung, enthaltende glykoproteine, verfahren zur herstellung und verwendungen
Nelson Ethanol protection against the catalase-depressing effect of 3-amino-1, 2, 4-triazole
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
BR0002726A (pt) Uso e preparação contendo derivados de hemoglobina para a determinação do volume do plasma e/ou do sangue
KR950003312A (ko) 연골세포 단백질
Brancaccio et al. Purification and partial characterization of a new 85 KDa amyloidosis-related protein in chronic hemodialysis
Sakai et al. Studies on the Gastric Juice Protein (I): On the" Peptide Portion" of the Gastric Juice by the Paper-Electrophoresis-Polarogram
RIDDLE The Blood Sugar During Remission in Pernicious Anemia
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
FI57112B (fi) Foerfarande foer framstaellning av antiinflammatoriska epsilon-n-karbamylorgoteiner
Butler Free radicals in molecular biology aging and disease (Aging, Volume 27)

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee